Bush Pharmacos Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 29-06-2024
- Paid Up Capital ₹ 0.45 M
as on 29-06-2024
- Company Age 36 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.25 M
as on 29-06-2024
- Satisfied Charges ₹ 1.15 M
as on 29-06-2024
- Revenue 101.09%
(FY 2017)
- Profit -65.90%
(FY 2017)
- Ebitda 3107.01%
(FY 2017)
- Net Worth 12.96%
(FY 2017)
- Total Assets -1.19%
(FY 2017)
About Bush Pharmacos
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.45 M.
The company currently has active open charges totaling ₹1.25 M. The company has closed loans amounting to ₹1.15 M, as per Ministry of Corporate Affairs (MCA) records.
Govinda Ajmera and Mukesh Ajmera serve as directors at the Company.
- CIN/LLPIN
U24232MP1988PTC004704
- Company No.
004704
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 1988
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Bush Pharmacos Pvt Ltd offer?
Bush Pharmacos Pvt Ltd offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Bath Tools, Face Wash, Herbal Face Wash, Ayurvedic, Herbal Oils and Cosmetics, Aloe Vera Cosmetics, Cosmetics, Hair & Beauty Products, Face Cream, Salon, Spa Kits & Equipments, Shaving Accessories.
Who are the key members and board of directors at Bush Pharmacos?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Govinda Ajmera  | Director | 20-Dec-2006 | Current |
| Mukesh Ajmera | Director | 15-Jul-2005 | Current |
Financial Performance and Corporate Structure Insights of Bush Pharmacos.
Bush Pharmacos Pvt Ltd, for the financial year ended 2017, experienced significant growth in revenue, with a 101.09% increase. The company also saw a substantial fall in profitability, with a 65.9% decrease in profit. The company's net worth Soared by an impressive increase of 12.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bush Pharmacos?
In 2017, Bush Pharmacos had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 22 Feb 2021 | ₹1.25 M | Open |
Dena Bank Sitlamata Bazar Branch Indore Creation Date: 24 Feb 2011 | ₹0.75 M | Satisfied |
Bank Of Maharashtra Creation Date: 19 Mar 2002 | ₹0.40 M | Satisfied |
How Many Employees Work at Bush Pharmacos?
Unlock and access historical data on people associated with Bush Pharmacos, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Mar 02, 2011, Bush Pharmacos has raised a total of ₹ 1.75 M, with the most recent deal valued at ₹ 1.75 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
